Aspartocin D is a minor analogue of the amphomycin complex, a family of lipopeptide antibiotics produced by Streptomyces canus, isolated and reported by researchers at Fujian Institute of Microbiology in China in 2014. Aspartocin D is active against Gram positive bacteria and is presumed to act by inhibiting bacterial cell wall peptidoglycan synthesis, however its bioprofile and potential utility has not been extensively investigated.
